Among all adverse drug reactions reported in clinical practice, which is the most common type in terms of overall frequency?

Explanation

## Frequency Distribution of Adverse Drug Reactions **Key Point:** Type A (Augmented) reactions account for approximately **80% of all adverse drug reactions** in clinical practice, making them by far the most common type. ### Comparative Epidemiology of ADR Types | ADR Type | Frequency | Characteristics | Examples | |----------|-----------|-----------------|----------| | **Type A (Augmented)** | **~80%** | Dose-dependent, predictable, exaggerated pharmacology | Bleeding on warfarin, hypoglycemia on insulin, dry mouth on anticholinergics | | **Type B (Bizarre)** | ~15–20% | Dose-independent, unpredictable, immune-mediated | Anaphylaxis, DRESS, SJS/TEN, serum sickness | | **Type C (Chronic)** | ~5% | Cumulative dose/duration-dependent | Tetracycline photosensitivity, methotrexate hepatotoxicity | | **Type D (Delayed)** | Rare | Teratogenic or carcinogenic | Thalidomide, methotrexate, diethylstilbestrol | | **Type E (End-of-dose)** | Uncommon | Withdrawal or rebound phenomena | Rebound hypertension on clonidine withdrawal | ### Why Type A Is Most Common **High-Yield:** Type A reactions are: 1. **Predictable** — occur in any patient given sufficient dose 2. **Dose-dependent** — severity correlates with drug concentration 3. **Related to pharmacology** — exaggeration of the drug's intended effect 4. **Manageable** — usually reversible by dose reduction or discontinuation **Mnemonic: ADEC** — **A**ugmented (most common, 80%), **D**elayed (rare), **E**nd-of-dose (uncommon), **C**hronic (5%), **B**izarre (15–20%, but not in alphabetical order — remember B is second most common). **Clinical Pearl:** In clinical practice, the vast majority of ADRs are preventable Type A reactions caused by: - Overdosing (renal/hepatic impairment not accounted for) - Drug–drug interactions - Polypharmacy in elderly patients - Failure to adjust dose for age, weight, or organ dysfunction This is why dose optimization and therapeutic drug monitoring are cornerstone strategies in ADR prevention.